October 2026 Monthly Report

Returns 31-Dec-12 to 31-Oct-26

	Norse Capital	All Ords Accum	Outperformance	Small Ords Accum	Outperformance
Inception	606.63%	232.50%	374.13%	106.42%	500.21%
Inception per annum	15.17%	9.07%	6.11%	5.38%	9.80%
CY2026 (ytd)	10.35%	2.93%	7.42%	-14.29%	24.64%
CY2025	4.13%	10.56%	-6.43%	24.96%	-20.83%
CY2024	45.23%	11.44%	33.78%	8.36%	36.87%
CY2023	17.73%	12.98%	4.75%	7.82%	9.90%
CY2022	-30.79%	-2.96%	-27.83%	-18.38%	-12.41%
CY2021	16.86%	17.74%	-0.88%	16.90%	-0.04%
CY2020	26.36%	3.64%	22.73%	9.21%	17.15%
CY2019	43.44%	24.06%	19.38%	21.36%	22.08%
CY2018	7.46%	-3.53%	10.99%	-8.67%	16.13%
CY2017	15.55%	12.47%	3.08%	20.02%	-4.46%
CY2016	9.31%	11.65%	-2.33%	13.18%	-3.87%
CY2015	36.80%	3.78%	33.02%	10.16%	26.65%
CY2014	10.81%	5.02%	5.79%	-3.81%	14.62%
CY2013	19.24%	19.66%	-0.41%	-0.76%	20.00%
1m	-0.99%	0.66%	-1.65%	-6.43%	5.45%
3m	6.86%	0.00%	6.87%	-3.89%	10.75%
6m	15.70%	3.30%	12.40%	-6.94%	22.64%
1y	1.10%	1.61%	-0.51%	-14.36%	15.47%
2y pa	12.63%	6.82%	5.81%	2.56%	10.07%
3y pa	24.66%	12.74%	11.92%	10.02%	14.64%
5y pa	6.18%	7.30%	-1.13%	0.64%	5.53%
7y pa	10.81%	8.01%	2.80%	4.05%	6.77%
10y pa	13.04%	9.31%	3.72%	5.91%	7.13%
12y pa	15.17%	8.32%	6.86%	6.33%	8.84%
Sharpe Ratio	0.88	0.56	1.57x	0.27	3.29x
Sortino Ratio	1.47	0.79	1.86x	0.38	3.91x
Annualised standard deviation	14.83%	13.16%		16.42%	
Highest monthly return	11.91%	10.16%		14.27%	
Largest monthly loss	-10.61%	-20.94%		-22.38%	
Largest drawdown	-36.68%	-27.33%		-29.11%	
% positive months	67.47%	66.27%		57.83%	

October saw some rotation out of tech and into underperforming sectors of equity markets resulting in a positive +0.7% performance for the All Ords (which has a lower technology exposure) vs -0.9% for the S&P500 and -5.3% for the Nasdaq Composite. The ASX Small Ords continued its poor 2026 performance with October down another -6.4%. Our portfolio came in at -1%.

Our enterprise software basket was the biggest detractor to October's performance, costing the portfolio -0.95% with CRWD shares -5.4%, DDOG -14.1% and RBRK +8.5%.

On an individual stock basis, GOOG was a notable detractor with the shares down -18.3% after posting results. Their +25% constant currency revenue growth fell slightly short of estimates but despite cloud revenue posting +103% growth, the market fixated on the continued slowing of search revenue. This revived fears of AI becoming an existential threat to Google's search monopoly. In addition, the continued AI capex build saw a second quarter of negative FCF with guidance for more AI capex. As with much of the AI-focused parts of the market, the eventual ROI (or not) on AI spend will be the determining factor; management have voiced confidence on that ROI (obviously, given the capex spend commitment).

The largest positive contribution came from PME, the shares +19.7% as they announced a couple of new contracts: a $43m 7-year contract with Virtua Health and a $24m 7-year contract with Billings Clinic. Pleasingly, the former included PME's newish cardiology offering.

Shorts and hedges added +0.7% while the +1.25% rise in the Aud-Usd cost the portfolio -0.4%

Portfolio Holdings:

Cash:	24.8% (AUD and USD)
AUD-USD currency exposure:	31.3%
Longs:	76.3%
Shorts:	-8.9%
Options delta:	-10.9%
Net exposure:	56.5%
Top 5 equities (alphabetical):	AAPL, CRWD, EOL, PME, RMD

Quite a bit shorter with net exposure dropping ~15% lower as I shorted the Nasdaq 100 (QQQ) outright. Got lucky with the timing ahead of the drop right at month end (and into November). Rolled out existing CRWD and NVDA puts and put spreads and added a couple of SPY and

AAPL put spreads as AAPL shares continued towards all-time highs. Traded against our TLX $16 puts before it dropped and bought more against those puts under $13.



